» Articles » PMID: 35759210

Using the Intranasal Route to Administer Drugs to Treat Neurological and Psychiatric Illnesses: Rationale, Successes, and Future Needs

Overview
Journal CNS Drugs
Specialties Neurology
Pharmacology
Date 2022 Jun 27
PMID 35759210
Authors
Affiliations
Soon will be listed here.
Abstract

While the intranasal administration of drugs to the brain has been gaining both research attention and regulatory success over the past several years, key fundamental and translational challenges remain to fully leveraging the promise of this drug delivery pathway for improving the treatment of various neurological and psychiatric illnesses. In response, this review highlights the current state of understanding of the nose-to-brain drug delivery pathway and how both biological and clinical barriers to drug transport using the pathway can been addressed, as illustrated by demonstrations of how currently approved intranasal sprays leverage these pathways to enable the design of successful therapies. Moving forward, aiming to better exploit the understanding of this fundamental pathway, we also outline the development of nanoparticle systems that show improvement in delivering approved drugs to the brain and how engineered nanoparticle formulations could aid in breakthroughs in terms of delivering emerging drugs and therapeutics while avoiding systemic adverse effects.

Citing Articles

Nano-formulated curcumin uptake and biodistribution in the fetal growth restricted newborn piglet brain.

Xu N, Wixey J, Chand K, Wong M, Nance E Drug Deliv Transl Res. 2025; .

PMID: 40053231 DOI: 10.1007/s13346-025-01830-y.


Nose to brain strategy coupled to nano vesicular system for natural products delivery: Focus on synaptic plasticity in Alzheimer's disease.

Maisto N, Mango D J Pharm Anal. 2025; 14(12):101057.

PMID: 39802402 PMC: 11718335. DOI: 10.1016/j.jpha.2024.101057.


Hyaluronic Acid-Based Hybrid Nanoparticles as Promising Carriers for the Intranasal Administration of Dimethyl Fumarate.

Serri C, Piccioni M, Guarino V, Santonicola P, Cruz-Maya I, Crispi S Int J Nanomedicine. 2025; 20():71-89.

PMID: 39802381 PMC: 11717652. DOI: 10.2147/IJN.S481917.


Enhancing Acute Migraine Treatment: Exploring Solid Lipid Nanoparticles and Nanostructured Lipid Carriers for the Nose-to-Brain Route.

Torres J, Silva R, Farias G, Sousa Lobo J, Ferreira D, Silva A Pharmaceutics. 2024; 16(10).

PMID: 39458626 PMC: 11510892. DOI: 10.3390/pharmaceutics16101297.


Physico-Chemical Characterization and Initial Evaluation of Carboxymethyl Chitosan-Hyaluronan Hydrocolloid Systems with Insulin Intended for Intranasal Administration.

Popescu R, Dinu-Pirvu C, Ghica M, Anuta V, Popa L Int J Mol Sci. 2024; 25(19).

PMID: 39408782 PMC: 11476560. DOI: 10.3390/ijms251910452.


References
1.
Daneman R, Prat A . The blood-brain barrier. Cold Spring Harb Perspect Biol. 2015; 7(1):a020412. PMC: 4292164. DOI: 10.1101/cshperspect.a020412. View

2.
Profaci C, Munji R, Pulido R, Daneman R . The blood-brain barrier in health and disease: Important unanswered questions. J Exp Med. 2020; 217(4). PMC: 7144528. DOI: 10.1084/jem.20190062. View

3.
Pardridge W . The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005; 2(1):3-14. PMC: 539316. DOI: 10.1602/neurorx.2.1.3. View

4.
Strolin Benedetti M, Whomsley R, Poggesi I, Cawello W, Mathy F, Delporte M . Drug metabolism and pharmacokinetics. Drug Metab Rev. 2009; 41(3):344-90. DOI: 10.1080/10837450902891295. View

5.
Homayun B, Lin X, Choi H . Challenges and Recent Progress in Oral Drug Delivery Systems for Biopharmaceuticals. Pharmaceutics. 2019; 11(3). PMC: 6471246. DOI: 10.3390/pharmaceutics11030129. View